Verastem (NASDAQ:VSTM) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01), Yahoo Finance reports.
Verastem (VSTM) traded down $0.04 during trading on Wednesday, reaching $3.32. The company’s stock had a trading volume of 188,221 shares, compared to its average volume of 676,254. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12. The stock has a market capitalization of $171.71, a price-to-earnings ratio of -2.05 and a beta of 2.25. Verastem has a one year low of $1.37 and a one year high of $5.71.
A hedge fund recently raised its stake in Verastem stock. Northern Trust Corp boosted its stake in shares of Verastem Inc (NASDAQ:VSTM) by 40.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,750 shares of the biopharmaceutical company’s stock after buying an additional 21,178 shares during the period. Northern Trust Corp owned 0.20% of Verastem worth $160,000 as of its most recent filing with the Securities & Exchange Commission. 33.22% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/14/verastem-vstm-announces-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.